Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,418,996

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Retain Envista Stock in Your Portfolio for Now

by Zacks Equity Research

NVST's Specialty Products and Technologies business' strong performance appears promising. Yet, a leveraged balance sheet is worrisome.

Zacks Equity Research

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

by Zacks Equity Research

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

Zacks Equity Research

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

by Zacks Equity Research

InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.

Moumi Mondal headshot

Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?

by Moumi Mondal

Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.

Indrajit Bandyopadhyay headshot

5 Medical Device Stocks That Survived the 2024 Market Volatility

by Indrajit Bandyopadhyay

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

Zacks Equity Research

ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

by Zacks Equity Research

AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.

Zacks Equity Research

ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial

by Zacks Equity Research

Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.

Zacks Equity Research

Veeva Systems Q3 Earnings & Revenues Beat, Operating Margin Up Y/Y

by Zacks Equity Research

VEEV's fiscal third-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls

by Zacks Equity Research

COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.

Zacks Equity Research

Reasons to Retain ZBH Stock in Your Portfolio for Now

by Zacks Equity Research

Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.

Zacks Equity Research

Reasons to Retain TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

What Makes Globus Medical (GMED) a New Buy Stock

by Zacks Equity Research

Globus Medical (GMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Stryker Gains 30.2% Year to Date: What's Driving the Stock?

by Zacks Equity Research

SYK continues to witness growth on the back of a robust product line and strategic acquisitions.

Zacks Equity Research

GEHC Stock May Gain Following the Launches of Aurora and Clarify DL

by Zacks Equity Research

GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.

Zacks Equity Research

Globus Medical (GMED) Up 2.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins

by Zacks Equity Research

Patterson Companies' overall topline in the second quarter of fiscal 2025 benefits from strength in its Animal Health segment.

Zacks Equity Research

GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL

by Zacks Equity Research

GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.

Zacks Equity Research

Reasons to Retain EYE Stock in Your Portfolio for Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.

Zacks Equity Research

New Health Coaching Service on questhealth.com Set to Boost DGX Stock

by Zacks Equity Research

Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.

Zacks Equity Research

NARI Stock Likely to Gain Following Reimbursement Approval in Japan

by Zacks Equity Research

Inari Medical announces reimbursement approval for ClotTriever Thrombectomy System in Japan and a new distribution partnership with Medikit.

Zacks Equity Research

RDNT Stock Up Post New Tie-Up to Boost Ultrasound Workflows With AI

by Zacks Equity Research

RadNet's latest collaboration aims to create an AI-powered SmartTechnology to improve patient experience and operational efficiency in ultrasound.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0

by Zacks Equity Research

Hologic upholds its focus on equity with new research findings on its Breast Imaging AI solution.

Zacks Equity Research

Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?

by Zacks Equity Research

PEN stays on investors' radars due to its robust portfolio expansion and international growth plans.